Loading...
•
Jun 30, 2023
Jaguar Health Q2 2023 Earnings Report
Reported a net revenue increase and an increased operating loss during the second quarter of 2023.
Key Takeaways
Jaguar Health reported a 36% increase in net revenue compared to Q1 2023, reaching $2.7 million, driven by sales of Mytesi® and Canalevia®-CA1. However, the loss from operations also increased to $8.1 million.
Net revenue increased by 36% compared to Q1 2023.
Combined net revenue for Mytesi® and Canalevia®-CA1 was approximately $2.7 million.
Loss from operations increased by $1.6 million to $8.1 million.
Top line results for the Phase 3 OnTarget trial expected in late October 2023.
Jaguar Health
Jaguar Health
Forward Guidance
Jaguar Health anticipates top line results from the OnTarget study in late October 2023 and potential expansion of Mytesi's indication in 2024.
Positive Outlook
- Top line results from the OnTarget study are expected in late October 2023.
- Potential expansion of Mytesi's indication in 2024.
- Data from proof-of-concept studies of crofelemer for MVID and SBS with intestinal failure will be available before the end of 2023 and in 2024.
- Potential for reimbursed early patient access to crofelemer for SBS or MVID in 2024.
- Phase 3 pivotal OnTarget trial of Mytesi completed patient enrollment.